X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1044) 1044
male (1033) 1033
prostatic neoplasms - drug therapy (834) 834
aged (522) 522
middle aged (472) 472
oncology (453) 453
estramustine - therapeutic use (410) 410
antineoplastic combined chemotherapy protocols - therapeutic use (403) 403
prostate cancer (377) 377
chemotherapy (358) 358
estramustine (347) 347
prostatic neoplasms - pathology (341) 341
estramustine - administration & dosage (311) 311
docetaxel (309) 309
urology & nephrology (255) 255
aged, 80 and over (248) 248
treatment outcome (240) 240
prostate-specific antigen - blood (230) 230
index medicus (222) 222
cancer (213) 213
carcinoma (210) 210
estramustine phosphate (202) 202
antineoplastic agents - therapeutic use (187) 187
mitoxantrone (186) 186
antineoplastic agents, hormonal - therapeutic use (180) 180
prostatic neoplasms - mortality (178) 178
adenocarcinoma - drug therapy (175) 175
phase-ii trial (170) 170
taxoids - administration & dosage (163) 163
mitoxantrone plus prednisone (150) 150
antineoplastic combined chemotherapy protocols - adverse effects (140) 140
estramustine - adverse effects (140) 140
prostatic neoplasms - blood (138) 138
prednisone (131) 131
prostatic neoplasms - therapy (131) 131
nitrogen mustard compounds - therapeutic use (129) 129
care and treatment (125) 125
taxoids - therapeutic use (125) 125
drug resistance, neoplasm (124) 124
clinical trials as topic (122) 122
trial (118) 118
drug administration schedule (116) 116
orchiectomy (116) 116
animals (109) 109
survival analysis (109) 109
androgen antagonists - therapeutic use (105) 105
phase-ii (105) 105
prostatic neoplasms - surgery (104) 104
bone neoplasms - secondary (103) 103
neoplasm metastasis (103) 103
therapy (100) 100
combined modality therapy (99) 99
survival rate (99) 99
disease progression (96) 96
neoplasms, hormone-dependent - drug therapy (93) 93
prognosis (89) 89
paclitaxel (86) 86
paclitaxel - administration & dosage (85) 85
survival (85) 85
radical prostatectomy (82) 82
administration, oral (81) 81
antigen (81) 81
men (80) 80
research (79) 79
oral estramustine (73) 73
disease-free survival (70) 70
neoplasm staging (69) 69
time factors (69) 69
adult (68) 68
metastasis (68) 68
pharmacology & pharmacy (68) 68
prostatic neoplasms - metabolism (64) 64
diethylstilbestrol - therapeutic use (63) 63
prospective studies (62) 62
adenocarcinoma - pathology (61) 61
vinblastine (61) 61
follow-up studies (60) 60
adenocarcinoma - secondary (59) 59
combination (59) 59
dose-response relationship, drug (59) 59
antineoplastic agents, hormonal - administration & dosage (58) 58
bone neoplasms - drug therapy (58) 58
prostatic neoplasms - radiotherapy (58) 58
drug therapy (57) 57
prostatectomy (56) 56
quality of life (56) 56
antineoplastic agents, phytogenic - therapeutic use (55) 55
castration (55) 55
drug therapy, combination (55) 55
medicine & public health (55) 55
retrospective studies (55) 55
clinical-trials (54) 54
hydrocortisone (54) 54
prednisone - administration & dosage (54) 54
randomized controlled trials as topic (54) 54
taxoids (54) 54
female (52) 52
mitoxantrone - administration & dosage (52) 52
radiotherapy (52) 52
taxoids - adverse effects (52) 52
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1011) 1011
Japanese (47) 47
German (23) 23
French (18) 18
Spanish (13) 13
Russian (4) 4
Hungarian (3) 3
Czech (2) 2
Italian (2) 2
Norwegian (2) 2
Polish (2) 2
Afrikaans (1) 1
Croatian (1) 1
Danish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA Cancer Journal for Clinicians, ISSN 0007-9235, 09/2012, Volume 62, Issue 5, pp. 299 - 308
There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than... 
GROWTH FACTOR/SCATTER FACTOR | LEUKEMIA GROUP-B | MITOXANTRONE PLUS PREDNISONE | PHASE-II TRIAL | ONCOLOGY | ORAL ESTRAMUSTINE PHOSPHATE | ABIRATERONE ACETATE | END-POINTS | RANDOMIZED CONTROLLED-TRIAL | ANTITUMOR-ACTIVITY | SIPULEUCEL-T | Castration - adverse effects | Prostate-Specific Antigen | Anilides - therapeutic use | Taxoids - pharmacology | Phenylthiohydantoin - therapeutic use | Cancer Vaccines - pharmacology | Humans | Tissue Extracts - pharmacology | Male | Antineoplastic Agents - therapeutic use | Androstenols - therapeutic use | Prostatic Neoplasms - therapy | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Radiopharmaceuticals - pharmacology | Pyridines - therapeutic use | Phenylthiohydantoin - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Radium - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | RANK Ligand - antagonists & inhibitors | Anilides - pharmacology | Pyridines - pharmacology | Radiopharmaceuticals - therapeutic use | Care and treatment | Drug therapy | Drug resistance | Laws, regulations and rules | Prostate cancer | Drug approval | Clinical trials | Chemotherapy | Castration | Pathogenesis
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2015, Volume 93, Issue 2, pp. 294 - 302
Purpose Long-term (LT) androgen suppression (AS) with radiation therapy (RT) is a standard treatment of high-risk, localized prostate cancer (PCa). Radiation... 
Radiology | Hematology, Oncology and Palliative Medicine | ONCOLOGY | COMPETING RISK | DEPRIVATION | ORAL ETOPOSIDE | GROUP PROTOCOL 92-02 | RADIOTHERAPY | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | III TRIAL | DURATION | ESTRAMUSTINE | PACLITAXEL | Prostatic Neoplasms - radiotherapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Hormonal - adverse effects | Early Termination of Clinical Trials | Neoplasm Grading | Time Factors | Chemotherapy, Adjuvant - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Etoposide - therapeutic use | Paclitaxel - therapeutic use | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Androgen Antagonists - therapeutic use | Aged | Combined Modality Therapy - methods | Estramustine - therapeutic use | Clinical trials | Radiotherapy | Health aspects | Adjuvant treatment | Radiation | Cancer | Index Medicus | PROSTATE | LUTEINIZING HORMONE | PATIENTS | NEOPLASMS | CLINICAL TRIALS | FAILURES | METASTASES | ANTIGENS | TOXICITY | COMPUTERIZED TOMOGRAPHY | CHEMOTHERAPY | LIBERINS | INHIBITION | DATA | HYPOTHESIS | RADIOLOGY AND NUCLEAR MEDICINE | ANDROGENS
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2016, Volume 34, Issue 4, pp. 474 - 480
Background Treatment options for patients with metastatic castration-resistance prostate cancer are unsatisfactory. Docetaxel monotherapy offers promising... 
Medicine & Public Health | Weekly chemotherapy | Docetaxel | Zoledronic acid | Oncology | Celecoxib | Pharmacology/Toxicology | Prostate cancer | APOPTOSIS | CELLS | DEFINITIVE RADIATION-THERAPY | RADICAL PROSTATECTOMY | RANDOMIZED CONTROLLED-TRIAL | MITOXANTRONE PLUS PREDNISONE | ONCOLOGY | CYCLOOXYGENASE-2 INHIBITOR CELECOXIB | PHARMACOLOGY & PHARMACY | EXPRESSION | ESTRAMUSTINE | SCHEDULES | Celecoxib - adverse effects | Bone Density Conservation Agents - adverse effects | Humans | Imidazoles - adverse effects | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Density Conservation Agents - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Celecoxib - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Cyclooxygenase 2 Inhibitors - adverse effects | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cyclooxygenase 2 Inhibitors - therapeutic use | Aged, 80 and over | Diphosphonates - therapeutic use | Aged | Imidazoles - therapeutic use | Diphosphonates - adverse effects | Taxoids - adverse effects | Complications and side effects | Dosage and administration | Research | Drug therapy | Studies | Medical research | Chemotherapy | Clinical trials | Pharmacology | Cancer therapies | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 2, pp. 149 - 158
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1147 - 1154
Summary Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy... 
Internal Medicine | EVERY 3 WEEKS | MEDICINE, GENERAL & INTERNAL | PAIN | SOLID TUMORS | END-POINTS | TAXANE | CHEMOTHERAPY | ESTRAMUSTINE | Prostatic Neoplasms - metabolism | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms - immunology | Antineoplastic Agents, Hormonal - therapeutic use | Treatment Failure | Neutropenia - chemically induced | Mitoxantrone - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Prostatic Neoplasms - pathology | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Biomarkers, Tumor - blood | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Infusions, Intravenous | Pain Measurement | Dosage and administration | Prednisone | Research | Drug therapy | Prostate cancer | Mitoxantrone hydrochloride | Studies | Chemotherapy | Medical imaging | Physicians | Family medical history | Radiation therapy | Clinical medicine | Cancer therapies
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 10/2006, Volume 97, Issue 10, pp. 970 - 976
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6, pp. e0157660 - e0157660
Journal Article